Two Viruses, One Body: How HIV-Positive New Yorkers Are Confronting the Long COVID Crisis Alone

When Marcus, a 47-year-old Bronx resident who has been HIV-positive since 2009, tested positive for COVID-19 in the winter of 2022, he assumed the illness would follow a predictable course. He was virally suppressed, his CD4 count was stable, and he had received three vaccine doses. What followed was anything but predictable. Eighteen months later, Marcus still experiences crushing fatigue, cognitive fog so severe he has lost two jobs, and a persistent shortness of breath that no pulmonologist has been able to fully explain. "I felt like I was invisible," he said. "The HIV doctors didn't know what to do with the COVID symptoms, and the COVID doctors didn't know what to do with the HIV."

Marcus is not alone. Across New York City, a growing cohort of HIV-positive individuals is grappling with what researchers are beginning to call a dual burden: the long-term consequences of COVID-19 infection layered onto an immune system already shaped by decades of viral activity, antiretroviral therapy, and in some cases, prior opportunistic illness. The clinical picture is complex, the research is nascent, and the systems designed to support these patients were not built for this moment.

What the Science Currently Tells Us

Long COVID — formally designated as Post-Acute Sequelae of SARS-CoV-2 infection, or PASC — is broadly defined as symptoms persisting beyond four weeks after an initial COVID-19 infection. These symptoms can include fatigue, neurological impairment, cardiovascular irregularities, and immune dysregulation. For the general population, estimates suggest that somewhere between 10 and 30 percent of COVID survivors develop some form of long-term symptoms. For people living with HIV, researchers suspect the rates may be higher, though robust longitudinal data remains limited.

A 2023 study published in Clinical Infectious Diseases found that HIV-positive individuals, even those with well-controlled viral loads, demonstrated elevated inflammatory markers following COVID-19 infection compared to HIV-negative counterparts. Researchers hypothesize that chronic immune activation — a hallmark of long-term HIV infection — may prime the body for a more dysregulated response to SARS-CoV-2. Additionally, some antiretroviral medications interact with the cytokine pathways implicated in long COVID, creating a pharmacological complexity that clinicians are still working to untangle.

Dr. Yolanda Ferreira, an infectious disease specialist affiliated with a major Manhattan hospital system, describes the situation plainly: "We are asking patients to be pioneers in a space where the medical literature is still catching up. That is an enormous burden to place on people who have already navigated one chronic illness."

The Gaps in Clinical Guidance

One of the most significant challenges facing HIV-positive New Yorkers with long COVID is the absence of unified clinical protocols. The Centers for Disease Control and Prevention and the National Institutes of Health have issued general long COVID guidance, but these frameworks rarely address the specific immunological context of HIV coinfection. Clinicians working in HIV care report receiving little formal instruction on how to modify long COVID treatment approaches for immunocompromised patients.

The result is a fragmented care landscape. Patients are frequently referred between infectious disease specialists, pulmonologists, cardiologists, and neurologists — each addressing a single system in isolation. For those whose HIV care is managed through community health centers, many of which operate on constrained budgets, the capacity to coordinate across specialties is often severely limited.

This fragmentation falls hardest on communities already navigating structural disadvantage. Black and Latino New Yorkers, who are disproportionately represented among both HIV-positive individuals and long COVID patients in the city, face the compounded burden of systemic healthcare inequities. Language barriers, insurance gaps, and geographic distance from specialized care further narrow their options.

Viral Persistence and the Immune Reservoir Question

Among the most pressing scientific questions is whether SARS-CoV-2 can establish a viral reservoir in HIV-positive individuals in ways analogous to HIV itself. Some researchers are investigating whether residual COVID viral particles persist in tissue long after the acute infection resolves, triggering ongoing immune activation. If confirmed, this would have significant implications for HIV-positive patients, whose immune systems may be less capable of clearing these reservoirs efficiently.

The parallel to HIV's own reservoir dynamics is not lost on longtime advocates. "We spent decades learning that HIV hides," noted one community health worker at a Harlem-based organization. "Now we're asking whether COVID does something similar, and whether having both changes the equation entirely. That question deserves serious federal research funding, and it is not getting it."

What New York's HIV Infrastructure Can — and Cannot — Do

New York City has one of the most developed HIV care infrastructures in the United States, built over decades of hard-won advocacy and public health investment. The Ryan White HIV/AIDS Program funds a network of care providers across all five boroughs. Community-based organizations offer wraparound services ranging from case management to mental health support. This infrastructure represents genuine achievement.

Yet that same infrastructure was designed around a specific model of chronic disease management — one centered on antiretroviral adherence, routine lab monitoring, and prevention of opportunistic infections. Long COVID introduces a set of symptoms and care needs that sit outside this established framework. Case managers trained in HIV care may have limited expertise in post-viral syndrome management. Clinics structured around quarterly HIV visits are not designed to provide the frequent, multidisciplinary follow-up that long COVID often demands.

Some organizations are beginning to adapt. Several community health centers in Brooklyn and Queens have begun training staff on long COVID screening and are piloting referral pathways specifically for HIV-positive patients. These efforts are promising, but they remain isolated and underfunded.

The Psychological Toll of Dual Diagnosis

Beyond the physical symptoms, the psychological weight of managing two chronic, stigmatized conditions simultaneously is considerable. Many HIV-positive New Yorkers spent years building strategies for disclosure, self-advocacy, and illness management. Long COVID disrupts those hard-earned equilibria.

"I had finally gotten to a place where HIV wasn't the first thing I thought about every morning," said Delia, a 53-year-old Queens resident who has been living with HIV for over two decades. "Now I wake up and I don't know if what I'm feeling is the HIV, the COVID, the medications, or just me getting older. It's exhausting in a way I don't have words for."

Mental health providers working within HIV care settings report an uptick in patients presenting with grief, health anxiety, and a profound sense of medical abandonment — the feeling that the healthcare system, having finally learned to treat HIV, has once again left them behind.

What Must Change

Addressing this emerging crisis requires action at multiple levels. Federally, the NIH's RECOVER initiative — the primary long COVID research program — must explicitly include HIV-positive cohorts in its longitudinal studies and ensure that findings are disaggregated by HIV status. Locally, the New York City Department of Health and Mental Hygiene should work with Ryan White-funded providers to develop integrated care protocols for patients managing both conditions.

Advocates are also calling on the state legislature to expand Medicaid reimbursement structures to support the kind of extended, multidisciplinary appointments that long COVID management requires. Without financial incentives aligned to clinical need, providers will continue to see these patients in systems that were not designed for them.

For Marcus, the policy debates are meaningful but distant. What he needs now is a doctor who can see both of his conditions at once — who understands that the two viruses share a body, and that treating them in isolation is not treatment at all. That kind of integrated, informed care is not yet the standard in New York City. It must become one.